Teva launches AHZANTIVE®, an EMA‑approved Eylea® biosimilar, across Europe to expand retinal disease treatment options and strengthen its biosimilars portfolio.
Written By: Disha Jadhao, BPharm
Reviewed By: Pharmacally Editorial Team
Teva Pharmaceutical Industries has launched AHZANTIVE® (aflibercept), a biosimilar to Eylea®, across major European markets including France, Germany, Spain, and the Netherlands. The rollout began in May 2026 and expands access to biosimilar aflibercept for patients with chronic retinal diseases, while marking Teva’s entry into ophthalmology. Additional launches are planned across Europe later this year.
Regulatory Approval and Partnerships
AHZANTIVE received European Commission approval in 2025 following analytical, non-clinical, and clinical studies demonstrating no clinically meaningful differences from the reference product in quality, efficacy, safety, and immunogenicity. As a biosimilar to Eylea, AHZANTIVE underwent a comprehensive comparability program that supported its approval across multiple ophthalmic indications.
The launch is supported by a semi-exclusive commercialization agreement with Klinge Biopharma GmbH and Formycon AG, covering key European territories and Israel. The partnership expands the availability of biosimilar treatment options for patients living with serious retinal diseases and provides healthcare professionals with an additional anti-VEGF therapy.
Clinical Indications and Mechanism
Aflibercept is a vascular endothelial growth factor (VEGF) inhibitor that blocks abnormal blood vessel growth and vascular leakage in the retina. By targeting VEGF signaling, the therapy helps reduce retinal swelling and preserve vision in patients with chronic retinal disorders.
AHZANTIVE is approved in the European Union for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), macular edema secondary to retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV). These chronic, progressive conditions are among the leading causes of vision impairment worldwide and often require long-term intravitreal treatment.
Market Impact and Access
Available as a pre-filled syringe, AHZANTIVE provides healthcare professionals with an additional treatment option in the growing anti-VEGF market. The introduction of biosimilar aflibercept could help improve patient access to biologic therapies while supporting healthcare systems through greater treatment choice and competition.
The launch also reflects increasing adoption of biosimilars in ophthalmology, where demand continues to grow as populations age and the prevalence of retinal diseases rises.
Commercial Expansion and Biosimilars Strategy
Commenting on the launch, Yolanda Tibbe, Global Head of Biosimilars at Teva, said, “Biosimilars play a critical role in sustainable healthcare systems. With this launch, we are expanding our biosimilars portfolio with an important treatment option for people living with serious conditions that can threaten sight.”
Teva currently markets 11 biosimilars globally and has 13 additional candidates in development across oncology, immunology, ophthalmology, and respiratory diseases. The addition of AHZANTIVE further strengthens the company’s position in the expanding global biosimilars market.
European Rollout and Market Expansion
With AHZANTIVE now entering multiple European markets, Teva continues to expand its ophthalmology footprint while reinforcing its presence in biosimilars. Additional launches are expected throughout 2026 as commercialization efforts broaden across the region, increasing the availability of biologic treatment options for patients with chronic retinal disorders.
Reference
About the Writer
Disha Sanjay Jadhao (LinkedIn) is a pharmacy graduate and healthcare writer with a strong interest in clinical documentation and simplifying healthcare information for better reader understanding. She is enthusiastic, adaptable, and eager to take on new challenges while contributing to clear, accurate, and engaging medical and pharmaceutical content.
